Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of G...

Full description

Bibliographic Details
Main Authors: Aaron Boster, Mary Pat Bartoszek, Colleen O’Connell, David Pitt, Michael Racke
Format: Article
Language:English
Published: SAGE Publishing 2011-09-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756285611422108